Connect with us

Headlines

FDA Approves Tear Production Device

“It produces tears within seconds after gently touching it to the outside of the nose and pressing the ‘on’ button.”

mm

Published

on

ISSAQUAH, WA — Olympic Ophthalmics announced that the U.S. Food and Drug Administration has approved its prescription neurostimulation technology to temporarily increase acute tear production in adults.

The technology, called iTEAR100, is an external neurostimulator approved to increase acute tear production.

Leadership, Empathy, and a Noble Cause
Webinars

Leadership, Empathy, and a Noble Cause

Shop! Masterclass Webinar: Sustainability for Retail: How Retailers Create Social, Environmental and Cultural Innovations
Sponsored Webinars

Shop! Masterclass Webinar: Sustainability for Retail: How Retailers Create Social, Environmental and Cultural Innovations

Human-Centric Design in a Digital World: Creating Unexpected Moments That Inspire, Educate, and Connect at Retail
Sponsored Webinars

Human-Centric Design in a Digital World: Creating Unexpected Moments That Inspire, Educate, and Connect at Retail

The neurostimulator is a standalone, pocket-size device requiring only a 30-second or less application to the skin of the external nasal region. It was approved via a “de novo” request to the FDA.

“Its application stimulates the trigeminal nerve, which results in activation of the parasympathetic nerve pathway that controls tear film homeostasis,” according to a press release from Olympic Ophthalmics.

The neurostimulator was stated to be well tolerated and effective at temporarily increasing acute tear production, the company stated. It will be supplied through eye care provider channels for adults who would benefit from increased production of tears. The most common adverse effects in clinical trials were headache and dizziness in 2 percent to 3 percent of subjects.

Advertisement

“Olympic Ophthalmics is a team of entrepreneurs, clinicians, and investors with deep expertise in ophthalmology, neuromodulation, and medical devices, brought together to develop devices to lower treatment costs and provide high value therapies for ophthalmic diseases,” said Dr. Michael Gertner, founder and CEO. “FDA clearance is an exciting milestone for our team and more importantly, for patients. It is just the beginning of a new class of neuromodulation technologies in eye care.”

The device “is easy and intuitive to use by patients,” said Dr. Cynthia Matossian, an investigator in the clinical studies and medical director at Matossian Eye Associates, an affiliate of Prism Vision Group. “It produces tears within seconds after gently touching it to the outside of the nose and pressing the ‘on’ button.”

FDA reviewed results from two pivotal studies, one of which was a double-masked, randomized, sham-controlled multi-center study and the second, a multi-center six-month single-arm study in which subjects used the stimulator twice per day.

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

SPONSORED VIDEO

Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular

Link partner: indobet autowin88 vegasslot77 mantra88 ligasedayu warungtoto login sbobet vegas4d indobet ingatbola88 ligaplay dewagg hoki368 qqnusa ligagg zeus138 bro138 bos88 ligaciputra